249 related articles for article (PubMed ID: 27355232)
1. The case for a national service for primary immune deficiency disorders in New Zealand.
Ameratunga R; Steele R; Jordan A; Preece K; Barker R; Brewerton M; Lindsay K; Sinclair J; Storey P; Woon ST
N Z Med J; 2016 Jun; 129(1436):75-90. PubMed ID: 27355232
[TBL] [Abstract][Full Text] [Related]
2. Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency.
Martin A; Lavoie L; Goetghebeur M; Schellenberg R
Transfus Med; 2013 Feb; 23(1):55-60. PubMed ID: 23167310
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency.
Windegger TM; Nghiem S; Nguyen KH; Fung YL; Scuffham PA
Vox Sang; 2019 Apr; 114(3):237-246. PubMed ID: 30883804
[TBL] [Abstract][Full Text] [Related]
4. Utilisation of intravenous immunoglobulin in New Zealand: a clinical audit.
Hutchinson D; Flanagan P; Charlewood R; Mitchell T
N Z Med J; 2006 Dec; 119(1246):U2340. PubMed ID: 17151714
[TBL] [Abstract][Full Text] [Related]
5. Clinical Profile, Dosing, and Quality-of-Life Outcomes in Primary Immune Deficiency Patients Treated at Home with Immunoglobulin G: Data from the IDEaL Patient Registry.
Kearns S; Kristofek L; Bolgar W; Seidu L; Kile S
J Manag Care Spec Pharm; 2017 Apr; 23(4):400-406. PubMed ID: 28345437
[TBL] [Abstract][Full Text] [Related]
6. Intravenous and subcutaneous immunoglobulin replacement: a two-way road. Optimizing healthcare quality in patients with primary immunodeficiencies.
Soler-Palacín P; Gasó-Gago I; Fernández-Polo A; Martín-Nalda A; Oliveras M; Martinez-Cutillas J; Figueras C
J Clin Immunol; 2014 Nov; 34(8):1015-7. PubMed ID: 25190197
[TBL] [Abstract][Full Text] [Related]
7. Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain.
Alsina L; Montoro JB; Moral PM; Neth O; Pica MO; Sánchez-Ramón S; Presa M; Oyagüez I; Casado MÁ; González-Granado LI
Eur J Health Econ; 2022 Apr; 23(3):551-558. PubMed ID: 34546485
[TBL] [Abstract][Full Text] [Related]
8. Why I use subcutaneous immunoglobulin (SCIG).
Shapiro RS
J Clin Immunol; 2013 Jan; 33 Suppl 2():S95-8. PubMed ID: 23264027
[TBL] [Abstract][Full Text] [Related]
9. Switching Patients to Home-Based Subcutaneous Immunoglobulin: an Economic Evaluation of an Interprofessional Drug Therapy Management Program.
Perraudin C; Bourdin A; Spertini F; Berger J; Bugnon O
J Clin Immunol; 2016 Jul; 36(5):502-10. PubMed ID: 27139500
[TBL] [Abstract][Full Text] [Related]
10. Clinical experiences in primary and secondary immunodeficiencies and immune-mediated conditions using Gammanorm(®).
Gardulf A
Immunotherapy; 2016 May; 8(5):633-47. PubMed ID: 27020964
[TBL] [Abstract][Full Text] [Related]
11. Home-based subcutaneous immunoglobulin therapy vs hospital-based intravenous immunoglobulin therapy: A prospective economic analysis.
Fu LW; Song C; Isaranuwatchai W; Betschel S
Ann Allergy Asthma Immunol; 2018 Feb; 120(2):195-199. PubMed ID: 29413344
[TBL] [Abstract][Full Text] [Related]
12. The spectrum of primary immunodeficiency disorders in Australia.
Baumgart KW; Britton WJ; Kemp A; French M; Roberton D
J Allergy Clin Immunol; 1997 Sep; 100(3):415-23. PubMed ID: 9314356
[TBL] [Abstract][Full Text] [Related]
13. Comparison of American and European practices in the management of patients with primary immunodeficiencies.
Hernandez-Trujillo HS; Chapel H; Lo Re V; Notarangelo LD; Gathmann B; Grimbacher B; Boyle JM; Hernandez-Trujillo VP; Scalchunes C; Boyle ML; Orange JS
Clin Exp Immunol; 2012 Jul; 169(1):57-69. PubMed ID: 22670779
[TBL] [Abstract][Full Text] [Related]
14. [Replacement therapy with subcutaneous immunoglobulin in primary immunodeficiency in children].
Pac M
Pol Merkur Lekarski; 2011 Jun; 30(180):413-6. PubMed ID: 21751550
[TBL] [Abstract][Full Text] [Related]
15. [The ESID Online Database for primary immunodeficiencies. First analyses with regard to Germany and Europe].
Knerr V; Gathmann B; Eades-Perner AM; Kindle G; Grimbacher B
Med Klin (Munich); 2008 Sep; 103(9):620-7. PubMed ID: 18813884
[TBL] [Abstract][Full Text] [Related]
16. Ten-year population trends of immunoglobulin use, burden of adult antibody deficiency and feasibility of subcutaneous immunoglobulin (SCIg) replacement in Hong Kong Chinese.
Kan AKC; Leung GMK; Chiang V; Au EYL; Lau CS; Li PH
Front Immunol; 2022; 13():984110. PubMed ID: 36591300
[TBL] [Abstract][Full Text] [Related]
17. Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages".
Bienvenu B; Cozon G; Hoarau C; Pasquet M; Cherin P; Clerson P; Hachulla E; Crave JC; Delain JC; Jaussaud R
Orphanet J Rare Dis; 2016 Jun; 11(1):83. PubMed ID: 27334100
[TBL] [Abstract][Full Text] [Related]
18. New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin.
Ameratunga R; Woon ST; Gillis D; Koopmans W; Steele R
Clin Exp Immunol; 2013 Nov; 174(2):203-11. PubMed ID: 23859429
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin use in immune deficiency in the UK: a report of the UKPID and National Immunoglobulin Databases.
Shillitoe B; Hollingsworth R; Foster M; Garcez T; Guzman D; Edgar JD; Buckland M
Clin Med (Lond); 2018 Oct; 18(5):364-370. PubMed ID: 30287427
[TBL] [Abstract][Full Text] [Related]
20. Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases.
Haddad É; Barnes D; Kafal A
Transfus Apher Sci; 2012 Jun; 46(3):315-21. PubMed ID: 22503304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
